ReviewBiology of reproduction2026
A role for the antioxidants coenzyme Q10 and pyrroloquinoline quinone in mitigating obesity-associated reproductive dysfunction†.
Review in Biology of reproduction, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Redox Imbalance in Gestational Diabetes Mellitus: Mechanistic Insights, Emerging Biomarkers, and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a rising public health concern in the United States, with significant implications for maternal and fetal health during pregnancy. Maternal obesity is associated with increased risks of miscarriage, reduced implantation and pregnancy rates, fetal anomalies, abnormal fetal growth, stillbirth, preeclampsia, gestational diabetes, hypertensive disorders, labor and wound complications, and maternal depression. Current strategies for managing these risks include pre-pregnancy weight loss, nutritional counseling and weight management during pregnancy, lifestyle modifications, and low-dose aspirin to reduce the risk of preeclampsia. The effects of these interventions remain limited, underscoring the need for novel therapeutic approaches. A growing number of preclinical studies suggest that antioxidants such as coenzyme Q10 and pyrroloquinoline quinone may be promising candidates to mitigate the oxidative stress and mitochondrial dysfunction associated with maternal obesity and its comorbidities. Coenzyme Q10 supports mitochondrial function, ovarian reserve, and placental function while reducing obesity-related complications such as preeclampsia and miscarriage. Pyrroloquinoline quinone enhances mitochondrial biogenesis, regulates fatty acid metabolism, and ameliorates inflammation, with preclinical studies showing improved fertility and pregnancy rates, as well as protective effects against the development of adult metabolic diseases in offspring of pregnancies complicated with obesity. Together, coenzyme Q10 and pyrroloquinoline quinone offer promising nutraceutical strategies to improve fertility and reproductive health, placental function, pregnancy outcomes, and long-term metabolic consequences in offspring. Mechanistic insights gained from the preclinical research may inform future clinical studies to explore the therapeutic potential and synergistic benefits of combined coenzyme Q10 and pyrroloquinoline quinone treatment during human pregnancy complicated by obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.